Bellevue startup, armed with $320 million, undertakes ambitious project to aid medical research
Regeneron, San Diego-based biotech company Illumina and 17 health systems invested in the $320 million round. Regeneron ...
stocknews7d
3 Genomic Stocks at the Forefront of Precision Medicine
Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...
Truveta on Unlocking Health Data: Vanguards of Health Care
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
FierceBiotech4d
Illumina posts mixed earnings report while dealing with China tariff fallout
After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...
Milwaukee Journal Sentinel9d
Here's why researchers think most people stop taking weight loss drugs within a year
The higher quit rate among non-diabetes patients is likely due to cost, according to researchers from Truveta, a Bellevue, Washington-based medical research company that teamed up with University ...
Seeking Alpha7d
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2024 Earnings Call Transcript
Regeneron does not undertake any obligation ... Importantly, our new strategic collaboration with Truveta is expected to dramatically expand our database to include up to an additional 10 million ...
Eagle-Tribune11d
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
BELLEVUE, Wash., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has ...